Radiation Life Science Major

Prof. Rae-Kwon Kim 김래권

---

Email : rkim@ust.ac.kr, rkim@kaeri.re.kr

Tel : +82-42-868-8967

2017 ~ present        Senior Researcher, KAERI

2018 ~ present      Associate Professor, Radiation Life Science, UST

Drug development (Anti-Cancer drug, Radiation sensitizer)

2002 ~ 2008       B.S.  Life Science, Yong In University

2008 ~ 2010       M.S. Biomedical Science, Kyung Hee University

2010 ~ 2015      Ph.D. Life Science, Hanyang University

2015 ~ 2017      Postdoc, MD Anderson Cancer Center, Houston, TX, USA

2019.03 ~ 2024.02  Excellent new research project (NRF, 500,000,000 won)

Google Scholar : https://scholar.google.co.kr/citations?user=J0AAf38AAAAJ&hl=ko&oi=ao

(International Journal, last 3 years)

• Yeon-Jee Kahm, In-Gyu Kim, Rae-Kwon Kim. Regulation of cancer stem cells by CXCL1, a chemokine whose secretion is controlled by MCM2. BMC Cancer. 2024 Mar 7;24(1):319.

• Yeon-Jee Kahm, In-Gyu Kim, Uhee Jung, Jei Ha Lee, Rae-Kwon Kim. Impact of KIF4A on Cancer Stem Cells and EMT in Lung Cancer and Glioma. Cancers. 2023 Nov 22;15(23):5523.

• Heabin Kim, Hyun-Taek Kim, Seung-Hyun Jung, Jong Won Han, Seonmi Jo, In-Gyu Kim, Rae-Kwon Kim, Yeon-Jee Kahm, Tae-Ik Choi, Cheol-Hee Kim, Jei Ha Lee. A Novel Anticancer Pepride Derived from Bryopsis plumosa Regulates Proliferation and Invasion in Non-Small Cell Lung Cancer Cells. Mar Drugs. 2023 Nov 24;21(12):607.

• Yeon-Jee Kahm, Rae-Kwon Kim. BIRC5: A Novel Therapeutic Target for Lung Cancer Stem Cells and Glioma Stem Cells. Biochem Biophys Res Commun. 2023 Nov 19;682:141-147.

• Yeon-Jee Kahm, Uhee Jung, Rae-Kwon Kim. Regulation of Cancer Stem Cells and Epithelial-Mesenchymal Transition by CTNNAL1 in Lung Cancer and Glioblastoma. Biomedicines. 2023 May 17;11(5):1462.

• Yeon-Jee Kahm, In-Gyu Kim, Rae-Kwon Kim. RanBP1: A Potential Therapeutic Target for Cancer Stem Cells in Lung Cancer and Glioma. Int J Mol Sci. 2023 Apr 6;24(7):6855.

• Heabin Kim, Seonmi Jo, In-Gyu Kim, Rae-Kwon Kim, Yeon-Jee Kahm, Seung-Hyun Jung, Jei Ha Lee. Effect of Copper Chelators via the TGF-β Signaling Pathway on Glioblastoma Cell Invasion. Molecules. 2022 Dec 13;27(24):8851.

• Yeon-Jee Kahm, Rae-Kwon Kim, Uhee Jung, In-Gyu Kim. Epithelial membrane protein 3 regulates lung cancer stem cells via the TGF‑β signaling pathway. Int J Oncol. 2021 Oct;59(4):80

• Jae Yeon Choi, Hyun Jeong Seok, Rae-Kwon Kim, Mi Young Choi, Su-Jae Lee, In Hwa Bae. miR-519d-3p suppresses tumorigenicity and metastasis by inhibiting Bcl-w and HIF-1α in NSCLC. Mol Ther Oncolytics. 2021 Jul 10;22:368-379.

• In-Gyu Kim, Jei-Ha Lee, Seo-Yeon Kim, Chang-Kyu Heo, Rae-Kwon Kim, Eun-Wie Cho. Targeting therapy-resistant lung cancer stem cells via disruption of the AKT/TSPYL5/PTEN positive-feedback loop. Commun Biol. 2021 Jun 23;4(1):778.
  

(Patents)

Domestic patent application

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee, JUNG Woo He. MCM2에 의한 암줄기세포의 형성 및 자가재생 조절 (The application number: 10-2024-0004291). 2024. 01

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee, JUNG Woo He. KIF4에 의한 암줄기세포의 형성 및 자가재생 조절 (The application number: 10-2024-0004290). 2024. 01

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee, JUNG Woo He. BIRC5에 의한 암줄기세포의 형성 및 자가재생 조절 (The application number: 10-2023-0188914). 2023. 12

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee, JUNG Woo He. CTNNAL1에 의한 암줄기세포의 형성 및 자가재생 조절(The application number: 10-2023-0188913). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Indian Patent application number: 3221714). 2024. 01

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (US Patent application number: 18/571623). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Singapore Patent application number: 11202309203Q). 2023. 11

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Japanese Patent application number: 3221714). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (EU Patent application number: 22825362.1). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Chinese Patent application number: 202280042376.1). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Canadian Patent application number: 3221714). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Brazil Patent application number: 1120230254574). 2023. 12

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (Australia Patent application number: 2022293217). 2023. 11

• KIM In Gyu, KIM Sung Chul, KIM Rae-Kwon, KAHM Yeon-Jee, KIM Bum Jin, SHIN Bung chul. 항 hTM4SF4 (human transmembrane 4 L six family member 4) 항-TM4SF4 인간화 항체 및 이의 용도 (The application number: 10-2022-0177553). 2022. 12

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee, JUNG Woo He. RanBP1에 의한 암줄기세포의 형성 및 자가재생 조절 (The application number: 10-2022-0177553). 2022. 12)

• KIM In Gyu, RU Chun Jae, KIM Min Kyu, KIM Rae-Kwon, PARK Whang Se, CHOI Moon Joo, KAHM Yeon-Jee, SHIN Bung Chul, JUNG Woo He. 항-TM4SF4 인간화 항체 및 이의 용도 (PCT application number: PCT/KR2022/008570). 2022. 06

• KIM In Gyu, RU Chun Jae, KIM Min Kyu, KIM Rae-Kwon, PARK Whang Se, CHOI Moon Joo, KAHM Yeon-Jee, SHIN Bung Chul, JUNG Woo He. 항-TM4SF4 인간화 항체 및 이의 용도 (The application number: 10-2022-0073674). 2022. 06

• KIM Rae-Kwon, KIM In Gyu, KAHM Yeon-Jee. WDR34 억제제를 포함하는 암줄기세포 성장 억제용 조성물 및 그 용도 (US Patent application number: 17/851500). 2022. 06

• KIM In Gyu, KIM Rae-Kwon, KAHM Yeon-Jee. EMP3에 의한 암줄기세포의 형성 및 자가재생 조절 (US Patent application number: 17/768906). 2022. 04

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (US Patent application number: 17/299156). 2021. 06

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (Japanese Patent application number: 2021-542571). 2021. 07

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (EU Patent application number: 20897028.5). 2021. 06

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (Chinese Patent application number: 202080006139.0). 2021. 05

• KIM In Gyu, RU Chun Jae, KIM Min Kyu, KIM Rae-Kwon, PARK Whang Se,CHOI Moon Joo, KAHM Yeon-Jee, SHIN Bung Chul, JUNG Woo He. Anti-TM4SF4 humanized antibody and uses thereof (The application number: 10-2021-0079629). 2021. 06

Domestic patent registration

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (Patent number: 10-2575994). 2023. 09

• KIM In Gyu, KIM Rae-Kwon, LEE Jei Ha, HUH Chang Kyu, KAHM Yeon-Jee, SHIN Bung Chul, CHO Eun-Wie, RU Chun Jae, KIM Min Kyu, CHOI Moon Joo. Anti-TM4SF4 antibody and uses thereof (Japanese Patent number: 7250938). 2023. 03

• KIM In Gyu, KIM Rae-Kwon, KAHM Yeon-Jee. Composition comprising EMP3 inhibitor for inhibiting growth of cancer stem cell and use thereof (Patent number: 10-2249757). 2021. 05

• 2022~present    Korean Society of Radiation Bioscience, Directorate

• Tech-Radiation Biology (UST, 2018-   )